Clinical Trials- Melanoma

 TITLE  PHASE  CONTACT  LOCATION
 A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab With or Without Everolimus for Therapy of Metastatic Malignant Melanoma
(Alliance N0879)
 II

Lisa Pfeifer RN
lisa.pfeifer@nmhs.org
402-354-8250

----------------------

Nebraska Cancer Research Center – Kelly Madcharo – kmadcharo@lmep.com

Nebraska Methodist Hospital
Omaha, NE; Nebraska Cancer Research Center, Lincoln NE
 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma (CTSU E1609)

Lisa Pfeifer RN
lisa.pfeifer@nmhs.org
402-354-8250

-------------------------

Good Samaritan – Michaela Sherbeck - michaelasherbeck@catholichealth.net;

------------------------

Rebecca Hadenfeldt, RN, BSN

RHadenfeldt@sfmc-gi.org

P: 308-398-6783

F: 309-398-3219

----------------------------------

 Cancer Research Center – Kelly Madcharo kmadcharo@lmep.com 

Nebraska Methodist Hospital
Omaha, NE; Good Samaritan Cancer Center, Kearney, NE; Saint Francis Cancer Treatment Center, Grand Island, NE; Nebraska Cancer Research Center, Lincoln, NE

 "A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon
α-2b for Resected High-risk Melanoma (E1609) *
TRAINING REQUIRED PRIOR TO ENROLLMENT" 
 III

 Marcia Grafe mgrafe@lmep.com

402-483-2827 

 Nebraska Cancer Research Center, Lincoln, NE; Lincoln Medical Education Partnership Lincoln, NE
 "A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma (N0879)"   II  

 Marcia Grafe mgrafe@lmep.com

402-483-2827

 Nebraska Cancer Research Center, Lincoln, NE; Lincoln Medical Education Partnership Lincoln, NE
 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma (E1609)  III

 Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

 Missouri Valley Cancer Consortium, Omaha, NE
 A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma (N0879)  II

 Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

 Missouri Valley Cancer Consortium, Omaha, NE
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b For Resected High-Risk Melanoma  III

Deborah Meyer, RN, BGS dmeyerk@unmc.edu(402) 559-6941

or Jolene Tijerina

 Nebraska Medical Center, Omaha, NE

 

 

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software